The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy of lurbinectedin plus atezolizumab as second-line treatment for advanced small-cell lung cancer: Results of the 2SMALL phase 1/2 study (NCT04253145).
 
Santiago Ponce Aix
Consulting or Advisory Role - Incyte (Inst); Pfizer (Inst)
Speakers' Bureau - AstraZeneca; Roche
 
Alejandro Navarro
Consulting or Advisory Role - Adium Pharma; Amgen; Boehringer Ingelheim; Bristol Myers Squibb Foundation; Eczacibasi; Pfizer; Takeda
Speakers' Bureau - AstraZeneca Spain; Roche
Expert Testimony - Hengenix; Medsir; Oryzon Genomics
Travel, Accommodations, Expenses - Boehringer Ingelheim; Pfizer; Roche
 
Maria Eugenia Olmedo Garcia
Consulting or Advisory Role - Abbvie/Genentech; Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; Janssen Oncology; Novartis; Pfizer; Roche/Genentech; Sanofi; Takeda
 
Laura Mezquita
Consulting or Advisory Role - AstraZeneca Spain; Janssen; MSD Oncology; Roche; Takeda
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb Spain; Janssen Oncology; MSD Oncology; Pfizer; Roche; Takeda
Research Funding - Amgen; AstraZeneca Spain; Bristol-Myers Squibb; Gilead Sciences (Inst); Inivata
Travel, Accommodations, Expenses - AstraZeneca; BMS; Roche; Takeda
 
Margarita Majem
Consulting or Advisory Role - AstraZeneca; BeiGene Beijing; Boehringer Ingelheim; Bristol-Myers Squibb; Helsinn Therapeutics; Janssen Oncology; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi; Takeda
Research Funding - AstraZeneca (Inst); BMS (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; MSD Oncology; Pfizer; Roche
 
David Vicente
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Gilead/Forty Seven; MSD Oncology; Novartis; Pfizer; Roche/Genentech
Travel, Accommodations, Expenses - AstraZeneca
 
Reyes Bernabé
No Relationships to Disclose
 
Alba Moratiel Pellitero
No Relationships to Disclose
 
Manuel Cobo
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Kyowa Kirin International; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi; Takeda
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Kyowa Kirin International; Lilly; MSD; Novartis; Novocure; Pierre Fabre; Roche; Sanofi; Takeda
 
Javier De Castro
Consulting or Advisory Role - Amgen; AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol Myers Squibb; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; GlaxoSmithKline; Janssen Oncology; Lilly; Merck Sharp and Dohme; Pfizer; Pierre Fabre; Regeneron; Roche; Takeda
Travel, Accommodations, Expenses - AstraZeneca Spain; Daiichi Sankyo/Astra Zeneca; Merck Sharp & Dohme; Pfizer; Roche
 
Silverio Ros
Honoraria - Ipsen, Sanofi; Ipsen, Sanofi
Consulting or Advisory Role - Bristol-Myers Squibb/Pfizer; Sanofi
Speakers' Bureau - Sanofi
Travel, Accommodations, Expenses - Ipsen
 
Marta Lopez Brea
No Relationships to Disclose
 
Rosario Campelo
Honoraria - Amgen; AstraZeneca; Bayer; BMS GmbH & Co. KG; Boehringer Ingelheim; Janssen; Lilly; MSD; Pfizer; Roche; Sanofi; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BMS GmbH & Co. KG; Boehringer Ingelheim; Janssen; Lilly; MSD; Pfizer; Roche; Sanofi; Taketa
Speakers' Bureau - Amgen; AstraZeneca; Bayer; BMS GmbH & Co. KG; Boehringer Ingelheim; F. Hoffmann LaRoche; Janssen; Lilly; MSD; Pfizer; Sanofi; Takeda
Research Funding - Amgen; AstraZeneca; Bayer; BMS GmbH & Co. KG; Boehringer Ingelheim; F. Hoffmann LaRoche; Janssen; Lilly; MSD; Pfizer; Sanofi; Takeda
 
Javier Baena
Honoraria - AstraZeneca Spain; AstraZeneca Spain; Bristol-Myers Squibb/Pfizer
Consulting or Advisory Role - Access Oncology; AstraZeneca Spain; Roche; Roche
Expert Testimony - Roche
Travel, Accommodations, Expenses - Janssen Oncology; MSD; MSD; Roche; Roche
 
Helena Bote
Honoraria - AstraZeneca; Janssen
Travel, Accommodations, Expenses - Johnson & Johnson/Janssen; Roche
 
Mercedes Herrera
Speakers' Bureau - AstraZeneca Spain
Travel, Accommodations, Expenses - Roche
 
Pedro Rocha
Travel, Accommodations, Expenses - AstraZeneca; BMS; Kyowa Kirin International; MSD; Roche
 
Jon Zugazagoitia
Honoraria - AstraZeneca Spain; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Guardant Health; NanoString Technologies; Pfizer; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Celgene; Guardant Health; Novartis; Novartis; Pfizer; Sanofi/Regeneron
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Guardant Health; MSD Oncology; NanoString Technologies; Pfizer; Pierre Fabre; Roche; Takeda
Research Funding - AstraZeneca (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb/Celgene; Janssen Oncology; Pfizer; Roche/Genentech; Sanofi
 
Enriqueta Felip
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Daiichi Sankyo Europe GmbH; Gilead Sciences; GlaxoSmithKline; ITeos Therapeutics; Johnson & Johnson/Janssen; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Regeneron; Roche; Turning Point Therapeutics
Speakers' Bureau - Amgen; AstraZeneca; Bristol Myers Squibb; Daiichi Sankyo; Genentech; Gilead Sciences; Johnson & Johnson/Janssen; Lilly; Medical Trends; Medscape; Merck Serono; Merck Sharp & Dohme; Novartis; Peervoice; Pfizer; Regeneron; Roche
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Roche
Other Relationship - GRIFOLS
(OPTIONAL) Uncompensated Relationships - "ETOP IBCSG Partners" Member of the Scientific Committee; “Medical writing assistance for this abstract was provided by Nimisha H. Bhoola, PhD, of Nucleus Global, an Inizio Company, and funded by F. Hoffmann-La Roche Ltd.”; Member of the Scientific Advisory Committee -Hospital Universitari Parc Taulí-; SEOM (Sociedad Española de Oncología Médica), President from 2021-2023
 
Luis Paz-Ares
Leadership - ALTUM Sequencing; Stab Therapeutics
Stock and Other Ownership Interests - Altum Sequencing; Stab therapeutics
Honoraria - Abbvie; Amgen; AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; Janssen; Lilly; Medscape; Merck Serono; MSD; Novartis; Pfizer; PharmaMar; Regeneron; Roche/Genentech; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AstraZeneca; AstraZeneca; Bayer; BMS; GlaxoSmithKline; Janssen; Lilly; Merck; Mirati Therapeutics; MSD; Novartis; Pfizer; Pharmamar; Regeneron; Roche; Sanofi; Takeda
Speakers' Bureau - Amgen; AstraZeneca; BeiGene; BMS; Daiichi Sankyo Europe GmbH; Lilly; Merck Serono; MSD Oncology; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); BMS (Inst); MSD (Inst); Pfizer (Inst); PharmaMar (Inst)
Other Relationship - Amgen (I); Astellas Pharma (I); Crinetics Pharmaceuticals (I); Esteve (I); HUTCHMED (I); Ipsen (I); ITM Isotope Technologies Munich (I); Merck (I); Novartis (I); Pfizer (I); Roche; Roche (I); Sanofi (I); SERVIER (I)